Brent Wood, MD, PhD

Professor of Pathology (Clinical Scholar)

Image of Brent Wood, MD, PhD
Is this your profile? Click to edit

Publications

  • Maturational dyssynchrony in benign B-cell precursors following lymphocyte depleting chemotherapy: A potential pitfall for B-lymphoblastic leukemia minimal/measurable residual disease (MRD) flow cytometry analysis Cytometry B Clin Cytom. 2024 Mar; 106(2):138-141. . View in PubMed
  • Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia Haematologica. 2024 Feb 01; 109(2):401-410. . View in PubMed
  • Updates on lymphoblastic leukemia/lymphoma classification and minimal/measurable residual disease analysis Semin Diagn Pathol. 2023 Nov; 40(6):457-471. . View in PubMed
  • Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia2022 Jul;36(7):1720-1748. Leukemia. 2023 Sep; 37(9):1944-1951. . View in PubMed
  • Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia medRxiv. 2023 Mar 27. . View in PubMed
  • Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children’s Oncology Group cohort trials Lancet Haematol. 2023 Feb; 10(2):e129-e141. . View in PubMed
  • Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study Blood. 2023 12 14; 142(24):2069-2078. . View in PubMed
  • Relative impact of residual cytogenetic abnormalities and flow cytometric measurable residual disease on outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia Haematologica. 2023 02 01; 108(2):420-432. . View in PubMed
  • Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells Blood Adv. 2023 02 28; 7(4):575-585. . View in PubMed
  • Measurable Residual Disease Detection in B-Acute Lymphoblastic Leukemia: The Children’s Oncology Group (COG) Method Curr Protoc. 2022 Mar; 2(3):e383. . View in PubMed
  • Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR) Pediatr Blood Cancer. 2022 11; 69(11):e29901. . View in PubMed
  • The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms Leukemia. 2022 07; 36(7):1720-1748. . View in PubMed
  • Sex-based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report Cancer. 2022 05 01; 128(9):1863-1870. . View in PubMed
  • Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL J Clin Oncol. 2022 03 20; 40(9):932-944. . View in PubMed
  • Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party Hemasphere. 2022 Jan; 6(1):e676. . View in PubMed
  • Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma J Clin Oncol. 2022 07 01; 40(19):2106-2118. . View in PubMed
  • Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children’s Oncology Group Pediatr Blood Cancer. 2021 04; 68(4):e28929. . View in PubMed
  • Fatal capillary leak syndrome in a child with acute lymphoblastic leukemia treated with moxetumomab pasudotox for pre-transplant minimal residual disease reduction Pediatr Blood Cancer. 2021 01; 68(1):e28574. . View in PubMed
  • Acute myeloid leukemia measurable residual disease detection by flow cytometry in peripheral blood vs bone marrow Blood. 2021 01 28; 137(4):569-572. . View in PubMed
  • Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia J Natl Cancer Inst. 2021 04 06; 113(4):408-417. . View in PubMed
  • Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation Cancers (Basel). 2020 Aug 19; 12(9). . View in PubMed
  • The minimal that kills: Why defining and targeting measurable residual disease is the “Sine Qua Non” for further progress in management of acute myeloid leukemia Blood Rev. 2020 09; 43:100650. . View in PubMed
  • Acute Myeloid Leukemia Minimal Residual Disease Detection: The Difference from Normal Approach Curr Protoc Cytom. 2020 06; 93(1):e73. . View in PubMed
  • Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease Leukemia. 2020 06; 34(6):1701-1705. . View in PubMed
  • Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML Leukemia. 2020 06; 34(6):1577-1587. . View in PubMed
  • Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia Bone Marrow Transplant. 2020 03; 55(3):669-672. . View in PubMed
  • Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force Cancer. 2020 02 01; 126(3):593-601. . View in PubMed
  • Applications of Flow Cytometric Immunophenotyping in the Diagnosis and Posttreatment Monitoring of B and T Lymphoblastic Leukemia/Lymphoma Cytometry B Clin Cytom. 2019 07; 96(4):256-265. . View in PubMed
  • Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1 Cytometry B Clin Cytom. 2019 01; 96(1):67-72. . View in PubMed
  • Validation of Minimal Residual Disease as Surrogate Endpoint for Event-Free Survival in Childhood Acute Lymphoblastic Leukemia JNCI Cancer Spectr. 2018 Oct; 2(4):pky069. . View in PubMed
  • Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD Am J Hematol. 2018 08; 93(4):546-552. . View in PubMed
  • A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy Cytometry B Clin Cytom. 2018 01; 94(1):112-120. . View in PubMed
  • Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children’s Oncology Group AALL0434 Methotrexate Randomization J Clin Oncol. 2018 10 10; 36(29):2926-2934. . View in PubMed
  • Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0622 J Clin Oncol. 2018 08 01; 36(22):2306-2314. . View in PubMed
  • Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party Blood. 2018 03 22; 131(12):1275-1291. . View in PubMed
  • Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis JAMA Oncol. 2017 Jul 13; 3(7):e170580. . View in PubMed
  • Methods of Detection of Measurable Residual Disease in AML Curr Hematol Malig Rep. 2017 12; 12(6):557-567. . View in PubMed
  • Ultrasensitive detection of acute myeloid leukemia minimal residual disease using single molecule molecular inversion probes Haematologica. 2017 09; 102(9):1549-1557. . View in PubMed
  • Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis Haematologica. 2017 05; 102(5):865-873. . View in PubMed
  • Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities Blood Rev. 2017 03; 31(2):63-75. . View in PubMed
  • Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission? J Clin Oncol. 2016 Feb 01; 34(4):329-36.. View in PubMed
  • Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation Biol Blood Marrow Transplant. 2016 11; 22(11):1974-1982. . View in PubMed
  • Evaluation of allogeneic transplantation in first or later minimal residual disease – negative remission following adult-inspired therapy for acute lymphoblastic leukemia Leuk Lymphoma. 2016 09; 57(9):2109-18. . View in PubMed
  • A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL08P1 J Pediatr Hematol Oncol. 2016 08; 38(6):409-17. . View in PubMed
  • Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232 J Clin Oncol. 2016 07 10; 34(20):2380-8. . View in PubMed
  • Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia J Clin Oncol. 2015 Apr 10; 33(11):1258-64. . View in PubMed
  • Apparent CD19 expression by natural killer cells: a potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia Cytometry B Clin Cytom. 2015 Mar; 88(2):145-7. . View in PubMed
  • Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing Mod Pathol. 2014 Nov; 27(11):1438-46. . View in PubMed
  • Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH Clin Cancer Res. 2014 Sep 01; 20(17):4540-8. . View in PubMed
  • Apparent CD19 expression by natural killer cells: A potential confounder for minimal residual disease detection by flow cytometry in B lymphoblastic leukemia Cytometry B Clin Cytom. 2014 Jul 21. . View in PubMed
  • Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia Leuk Res Treatment. 2014; 2014:421723. . View in PubMed
  • Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children’s oncology group studies: a report from the children’s oncology group J Clin Oncol. 2013 Sep 20; 31(27):3397-402. . View in PubMed
  • Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission Blood. 2013 Sep 05; 122(10):1813-21. . View in PubMed
  • High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia Sci Transl Med. 2012 May 16; 4(134):134ra63. . View in PubMed
  • Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia J Clin Oncol. 2011 Mar 20; 29(9):1190-7. . View in PubMed
  • Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection Cytometry B Clin Cytom. 2010 May; 78(3):139-46. . View in PubMed